IE801023L - Pyrimidinylamino diazacycloalkenes - Google Patents

Pyrimidinylamino diazacycloalkenes

Info

Publication number
IE801023L
IE801023L IE801023A IE102380A IE801023L IE 801023 L IE801023 L IE 801023L IE 801023 A IE801023 A IE 801023A IE 102380 A IE102380 A IE 102380A IE 801023 L IE801023 L IE 801023L
Authority
IE
Ireland
Prior art keywords
diazacycloalkenes
pyrimidinylamino
compounds
nitrogen
separates
Prior art date
Application number
IE801023A
Other versions
IE49803B1 (en
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of IE801023L publication Critical patent/IE801023L/en
Publication of IE49803B1 publication Critical patent/IE49803B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of the formula I <IMAGE> in which Py represents an optionally substituted 4-or 5-pyrimidinyl radical bonded via a carbon atom to the nitrogen atom, R1 and R2 independently of one another represent hydrogen, lower alkyl or lower alkenyl, and Alk represents lower alkylene which separates the two nitrogen atoms by 2 to 4 carbon atoms, their tautomeric compounds and salts, exhibit hypotensive and antihypertensive effects. [EP0019811A1]
IE1023/80A 1979-05-18 1980-05-16 4-or 5-pyrimidinyl-amino-1,3-diaza-2-cycloalkenes,processes for their preparation,pharmaceutical preparations containing these compounds,and their use in therapeutics IE49803B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH466979 1979-05-18

Publications (2)

Publication Number Publication Date
IE801023L true IE801023L (en) 1980-11-18
IE49803B1 IE49803B1 (en) 1985-12-25

Family

ID=4280399

Family Applications (1)

Application Number Title Priority Date Filing Date
IE1023/80A IE49803B1 (en) 1979-05-18 1980-05-16 4-or 5-pyrimidinyl-amino-1,3-diaza-2-cycloalkenes,processes for their preparation,pharmaceutical preparations containing these compounds,and their use in therapeutics

Country Status (21)

Country Link
EP (1) EP0019811A1 (en)
JP (1) JPS55154971A (en)
KR (1) KR830002757A (en)
AR (1) AR228256A1 (en)
AU (1) AU5848480A (en)
DD (1) DD150609A5 (en)
DK (1) DK214480A (en)
ES (1) ES8104279A1 (en)
FI (1) FI801600A7 (en)
GB (1) GB2052487B (en)
GR (1) GR68453B (en)
IE (1) IE49803B1 (en)
IL (1) IL60086A (en)
MA (1) MA18829A1 (en)
NO (1) NO801469L (en)
NZ (1) NZ193730A (en)
OA (1) OA06533A (en)
PL (1) PL224313A1 (en)
PT (1) PT71251A (en)
ZA (1) ZA802909B (en)
ZW (1) ZW11880A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) * 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
DE3829469A1 (en) * 1988-08-31 1990-03-01 Bayer Ag METHOD FOR THE PRODUCTION OF SUBSTITUTED N-AZINYL-N'-SULFONYL-ISOTHIO-UREAS AND N-AZINYL-IMINODITHIOCARBONIC ACID-S, S-DIESTER AS INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION
AU9302298A (en) * 1997-09-03 1999-03-22 Eli Lilly And Company Pyrimidine derivatives
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
NZ526472A (en) 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
BR0206844A (en) * 2001-01-31 2005-07-12 Synaptic Pharma Corp Use of gal3 receptor antagonists for the treatment of depression and / or anxiety and compounds used in such methods.
DK1483247T3 (en) 2002-03-13 2009-08-17 Euro Celtique Sa Aryl-substituted pyrimidines and their use
AU2003218215A1 (en) 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
AU2003214110A1 (en) * 2002-03-15 2003-09-29 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
DK1532145T3 (en) 2002-08-02 2007-01-15 Vertex Pharma Pyrazole preparations useful as inhibitors of GSK-3
WO2004072029A2 (en) 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
AU2006279376B2 (en) 2005-08-18 2011-04-14 Vertex Pharmaceuticals Incoporated Pyrazine kinase inhibitors
EP1954277B1 (en) 2005-11-03 2017-01-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
MX2009004807A (en) 2006-11-02 2009-06-15 Vertex Pharma Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases.
NZ577768A (en) 2006-12-19 2012-01-12 Vertex Pharma Aminopyrimidines useful as inhibitors of protein kinases
MX2009009592A (en) 2007-03-09 2009-11-10 Vertex Pharma Aminopyridines useful as inhibitors of protein kinases.
ATE526328T1 (en) 2007-03-09 2011-10-15 Vertex Pharma AMINOPYRIMIDINES SUITABLE AS INHIBITORS OF PROTEIN KINASES
MX2009009590A (en) 2007-03-09 2009-11-10 Vertex Pharma Aminopyrimidines useful as inhibitors of protein kinases.
AU2008240313A1 (en) 2007-04-13 2008-10-23 Aj Park Aminopyrimidines useful as kinase inhibitors
JP5389786B2 (en) 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド Aminopyrimidines useful as kinase inhibitors
AU2008247592A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
CN101790532B (en) 2007-07-31 2013-11-20 沃泰克斯药物股份有限公司 Preparation method of 5-fluoro-1H-pyrazolo [3,4-b ] pyridine-3-amine and derivatives thereof
WO2010027921A1 (en) 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
ES2467108T3 (en) * 2008-12-09 2014-06-11 Gilead Sciences, Inc. Toll type receiver modulators
KR102328682B1 (en) 2018-08-27 2021-11-18 주식회사 대웅제약 Novel heterocyclicamine derivatives and pharmaceutical composition comprising the same
JP2023549394A (en) * 2020-11-12 2023-11-24 スリールセータ エーハゥーエッフ Novel treatments for attention-deficit/hyperactivity disorder
CN121494792A (en) * 2026-01-14 2026-02-10 山东国邦药业有限公司 A method for preparing 5-methoxy-4,6-dihydroxypyrimidine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754832A (en) * 1969-08-14 1971-02-15 Beecham Group Ltd IMINAZOLINES

Also Published As

Publication number Publication date
GR68453B (en) 1981-12-30
NO801469L (en) 1980-11-19
GB2052487A (en) 1981-01-28
GB2052487B (en) 1983-05-11
PT71251A (en) 1980-06-01
IL60086A (en) 1984-03-30
MA18829A1 (en) 1980-12-31
ZW11880A1 (en) 1980-12-17
PL224313A1 (en) 1981-02-13
EP0019811A1 (en) 1980-12-10
NZ193730A (en) 1982-12-21
KR830002757A (en) 1983-05-30
IL60086A0 (en) 1980-07-31
JPS55154971A (en) 1980-12-02
ES491514A0 (en) 1981-04-16
OA06533A (en) 1981-07-31
ES8104279A1 (en) 1981-04-16
DK214480A (en) 1980-11-19
ZA802909B (en) 1981-05-27
DD150609A5 (en) 1981-09-09
IE49803B1 (en) 1985-12-25
AU5848480A (en) 1980-11-20
AR228256A1 (en) 1983-02-15
FI801600A7 (en) 1981-01-01

Similar Documents

Publication Publication Date Title
IE801023L (en) Pyrimidinylamino diazacycloalkenes
ES8700672A1 (en) Phenobarbital and carbamazepine enzyme inhibitors.
KR850006404A (en) Process for preparing nitro methylene derivative
DE3579110D1 (en) MUSTARD GAS DERIVATIVES OF C-6 AMINOGALACTOS AND THEIR USE.
ES8507507A1 (en) Substituted 2-mercapto-imidazoles and their preparation and use.
ES2012646A6 (en) Pyridazinone derivatives.
ES8705412A1 (en) Furan derivatives having anti-ulcer activity.
ES466532A1 (en) Antihypertensive 1-substituted-4-(2-oxo-1-imidazolidinyl) piperidines
ES8707525A1 (en) Isoindolinyl-alkyl-piperazines
ES485153A1 (en) 6-Arylpyridazine-3-ones, pharmaceutical compositions containing them and process for their preparation.
IE800253L (en) Pyridazinones.
KR920004392A (en) Fluoroethylcamptothecin derivatives
AU555533B2 (en) Substituted thiazolidinyl esters of mineral acids
DE3560110D1 (en) Derivatives of 2-alkoxyaminosulfonylbenzenesulfonylurea
ES8505935A1 (en) Hypoglycaemic and hypolipidaemic benzamide substituted (1H-) imidazole derivatives and compositions
IE46279L (en) Sulphamoylbenzoic acids.
AU555657B2 (en) 7alpha-alkoxycarbonyl-15beta, 16beta-methylene-4- androstenes
IE780982L (en) 4-hydroxythiazoline-2-thiones.
ES8504181A1 (en) Piperidinoquinoxaline derivatives, their preparation and use.
ES8603396A1 (en) Benzoylurea derivatives and intermediates.
GR3004473T3 (en)
ES8308875A1 (en) 4-Aminomethyl-5-acyl-1,3-dihydro-2H-imidazol-2-ones.
IL86665A0 (en) Mitomycin analogs
ES8102110A1 (en) 1,2,3-Thiadiazol-5-yl-thioglycolic acid, its derivatives and process for their preparation.
ES8704896A1 (en) 1,3,4-Trisubstituted azacycloalkanes or azacycloalkenes.